Filing Details

Accession Number:
0001179110-14-012790
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-12 21:49:03
Reporting Period:
2014-08-08
Filing Date:
2014-08-12
Accepted Time:
2014-08-12 20:49:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1061027 Sunesis Pharmaceuticals Inc SNSS Pharmaceutical Preparations (2834) 943295878
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1461466 Dayton Misfeldt C/O Bay City Capital Llc
750 Battery Street, Suite 400
San Francisco CA 94111
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-08-08 662,378 $6.62 4,868,792 No 4 S Indirect See footnotes.
Common Stock Disposition 2014-08-08 12,622 $6.62 92,780 No 4 S Indirect See footnotes.
Common Stock Disposition 2014-08-11 31,009 $6.90 4,837,783 No 4 S Indirect See footnotes.
Common Stock Disposition 2014-08-11 591 $6.90 92,189 No 4 S Indirect See footnotes.
Common Stock Disposition 2014-08-12 36,406 $6.77 4,801,377 No 4 S Indirect See footnotes.
Common Stock Disposition 2014-08-12 694 $6.77 91,495 No 4 S Indirect See footnotes.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnotes.
No 4 S Indirect See footnotes.
No 4 S Indirect See footnotes.
No 4 S Indirect See footnotes.
No 4 S Indirect See footnotes.
No 4 S Indirect See footnotes.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,515 Indirect See footnotes.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $6.71 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.
  2. The reporting person is a partner of Bay City Capital LLC, A Delaware limited liability company ("BCC"). BCC is the manager of Bay City Capital Management V LLC, a Delaware limited liablity company ("Management V"). Management V is the general partner of Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P.,a Delaware limited partnershp ("Co-Investment V") and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held. Mr. Misfeldt, BCC and Management V disclaim beneficial ownership with respect to the securities reported in this Form 4, except to the extent of their pecuniary interest therein.
  3. These securities are held by Fund V.
  4. These securities are held by Co-Investment V.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.87 to $6.94. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote five (5) of this Form 4.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $6.925 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote six (6) of this Form 4.
  7. These securities are held by BCC.